illumina - kn

Enhanced compatibility, interpretation, and precision.

Illumina Connected Insights, Illumina’s flagship platform for oncology research variant interpretation and reporting, has evolved significantly over the past few years to empower our customers on their precision oncology journey. Illumina’s investment in turnkey oncology informatics solutions is one of many ways in which we continuously commit to enabling research for applications such as MRD, risk stratification, and tumor subtyping. Our latest release of Connected Insights version 5.2 brings that and more, making NGS accessible to a wider range of oncology labs with more accurate, meaningful answers. 

The Illumina Software and Informatics team has been hard at work over the past year, continuously building on recent innovation within the Connected Software portfolio. Latest updates provide our customers with breakthrough solutions for the most accurate and efficient analysis and interpretation possible.

Last month, Illumina released Connected Insights v5.1, providing oncology customers with new variant curation capabilities that make using our flagship oncology interpretation platform even easier to use. Building on version 5.0 and earlier releases, the latest iteration of Connected Insights makes clinical research variant interpretation more powerful for a range of oncology use cases such as heme malignancy clinical research.

Hematological malignancies represent an important field within cancer genomics research, helping researchers better understand the molecular drivers and etiology behind blood cancers. While Illumina has supported heme malignancy research for more than a decade, new breakthrough innovations within Illumina’s informatics solutions for oncology, DRAGEN secondary analysis and Illumina Connected Insights, now drive more powerful, comprehensive interpretation of heme NGS data than ever.

Hematologic malignancies account for a large number of new cancer cases diagnosed in the United States each year, at around 9.5%. Characterization of genomic mutations at the many different stages of hematopoietic differentiation can help better understand the molecular drivers behind distinct tumor subtypes and disease etiology of blood cancers, unlocking new insights into myeloma, lymphoma, and leukemia-associated genes. In contrast to traditional single-gene methods, targeted and whole genome next-generation sequencing (NGS) offers significant advancements in sensitivity and scale, providing greater visibility into important drivers of hematologic malignancies.

Connected Insights version 5.0 unlocks key new functionality for somatic oncology research applications, including AI algorithms to support variant prioritization and oncogenicity prediction, as well as enriched visualization and curation capabilities. See the latest software release in action by requesting a demo by a technical specialist.